SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Frédéric Chopin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrédéric Chopin
Date of birth1810-03-01
IdentifiersMRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845
Document date1838-04-07
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for the alternatives. [S]

History of Present Illness

Mr. Chopin returns after nineteen days of treatment, all observed by video. The night sweats stopped in the second week, he has had no fever for ten days and no blood in his sputum for twelve, and his cough is now occasional. He had mild nausea in the first week, eased by taking the tablets in the middle of breakfast, and his urine and tears are orange as expected. He has no tendon pain, tingling, yellowing, dark urine, or rash. The three sputum smears collected in the third week were all negative, and the health department released him from isolation two days ago; he will start teaching in his studio again this week, beginning with eight lessons. The baseline cultures are growing Mycobacterium tuberculosis complex, and the molecular tests show no mutations for isoniazid or fluoroquinolone resistance. He has seen the dietitian twice and drinks two supplements a day in the afternoon and evening. His mood is better now that he can see his students. The sweat chloride test was done this morning. [S]

ElementDetail
TreatmentNineteen of nineteen doses observed
Infection controlThree negative smears; released from isolation; teaching again this week
MicrobiologyCultures growing M. tuberculosis complex; no isoniazid or fluoroquinolone resistance mutations
Weight49.6 kg, up 1.1 kg

Review of Systems

SystemResultFinding
RespiratoryPositiveOccasional cough; no blood for twelve days
ConstitutionalNegativeNo fever or night sweats; appetite returning
GastrointestinalNegativeNausea gone; no abdominal pain or jaundice
MusculoskeletalNegativeNo tendon or joint pain
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood better; no thoughts of suicide or self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route1838-03-20 to 1838-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route1838-03-20 to 1838-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route1838-03-20 to 1838-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route1838-03-20 to 1838-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1838-03-20 to 1838-07-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1838-04-07Body height170cmS
1838-04-07Body weight49.6kgS
1838-04-07Body mass index (BMI) [Ratio]17.2kg/m2S
1838-04-07Systolic blood pressure106mm[Hg]S
1838-04-07Diastolic blood pressure66mm[Hg]S
1838-04-07Heart rate86/minS
1838-04-07Respiratory rate16/minS
1838-04-07Body temperature37CelS
1838-04-07Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1838-04-07Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L7-56 U/LNormalS
1838-04-07Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-40 U/LNormalS
1838-04-07Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
1838-04-07Chloride [Moles/volume] in Sweat18mmol/L<=29 mmol/LNormalS
1838-04-07Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry142mg/dL100-190 mg/dLNormalS

Physical Exam

Vital signs recorded on 1838-04-07; see the Vital Signs section. [S]

SystemFinding
GeneralThin, brighter; weight 49.6 kg; temperature 37.0 °C
EyesNo icterus
RespiratoryA few crackles at the right apex; no bronchial breathing
MusculoskeletalTendons non-tender
NeurologicalNormal sensation in the fingers and feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsEvery visitCompleted todayOccasional cough; no fever, sweats, or blood
ExaminationWeight, with the pyrazinamide dose checked against the weight bandMonthlyCompleted today49.6 kg; pyrazinamide band unchanged
Medication safetyAdverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluidsEvery visitCompleted todayEarly nausea resolved; no tendon pain, tingling, rash, or jaundice
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin)Completed todayALT 34, AST 31 U/L, bilirubin 0.8 mg/dL, all normal
LaboratorySputum acid-fast smear and cultureBaseline, then monthly until two consecutive cultures are negativeCompleted todayThree smears in the third week negative; baseline cultures growing M. tuberculosis complex; third-week cultures pending
LaboratoryRapid molecular testing for isoniazid and fluoroquinolone resistanceAt baselineCompleted todayNo isoniazid (katG, inhA) or fluoroquinolone (gyrA, gyrB) resistance mutations
LaboratoryPhenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin)At baselineOrderedSet up on the baseline isolate; pending
Medication safetyDoses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months)Every visitCompleted todayNineteen of nineteen doses observed
Self-managementHome airborne isolation and the release criteriaUntil three negative smears, clinical improvement, and two weeks of treatmentCompleted todayRelease criteria met; released by the health department two days ago
ReferralContact investigation (students, friends, close contacts)Led by the health department from diagnosisReferredIn progress with the health department; no results in his record
Self-managementNutrition: dietitian, intake, supplement drinksEvery visit until weight is restoredCompleted todayTwo dietitian visits; two supplement drinks a day, apart from the dose
LaboratorySweat chloride and serum alpha-1 antitrypsinOnce, to address the alternativesCompleted todaySweat chloride 18 mmol/L; alpha-1 antitrypsin 142 mg/dL; both normal
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentNot indicatedNext at two months; mood better today

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017); American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)

Follow-up: End-of-intensive-phase review in about five weeks, with the two-month sputum culture, liver tests, a blood count, and the PHQ-9. Next scheduled visit 1838-05-15: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. [S]